New Medication Effective Against Chronic Hives

Sunday, 06 Oct 2013 10:10 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study.

The third and final late-stage study of omalizumab for treating the skin disease chronic spontaneous urticaria (CSU) found the drug was nearly twice as effective versus a placebo in improving life quality within 12 weeks of treatment, while also significantly reducing itch and hives caused by the condition.

Novartis said it had filed applications for the approval of omalizumab for treating patients with CSU to U.S. and European Union health authorities in the third quarter.
 
Omalizumab, which is also known as Xolair, is already approved for treating severe asthma.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Dallas Ebola Patient Vomited Outside Apartment

Wednesday, 01 Oct 2014 18:59 PM

Two days after he was sent home from a Dallas hospital, the man who is the first person to be diagnosed with Ebola in th . . .

Jealous, Moody Women Have Higher Alzheimer's Risk: Study

Wednesday, 01 Oct 2014 18:11 PM

Middle-aged women with a neurotic personality style and prolonged stress may have a heightened risk of developing Alzhei . . .

Living Near Highway Raises High Blood Pressure Risk

Wednesday, 01 Oct 2014 18:04 PM

Living close to a major highway may raise your risk for high blood pressure, a new study suggests.
Among more than  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved